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ABSTRACT
Objective of the study was to test the efficacy, safety,
and tolerability of two single doses of Epoetin alfa in
patients with Friedreich’s ataxia. Ten patients were
treated subcutaneously with 600 IU/kg for the first
dose, and 3 months later with 1200 IU/kg. Epoetin alfa
had no acute effect on frataxin, whereas a delayed and
sustained increase in frataxin was evident at 3 months
after the first dose (135%; P < 0.05), and up to 6
months after the second dose (154%; P < 0.001). The
treatment was well tolerated and did not affect hemato-
crit, cardiac function, and neurological scale. Single
high dose of Epoetin alfa can produce a considerably
larger and sustained effect when compared with low
doses and repeated administration schemes previously
adopted. In addition, no hemoglobin increase was
observed, and none of our patients required phlebot-
omy, indicating lack of erythropoietic effect of single
high dose of erythropoietin. VC 2010 Movement Disorder
Society
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Friedreich’s ataxia (FA) is an autosomal recessive
ataxia1 caused by a trinucleotide GAA expansion in
the first intron of the FXN gene.2 The gene encodes for
a 210aa mitochondrial protein called frataxin, whose
mRNA and protein levels are severely reduced in FA.3
It has been suggested that frataxin is involved in iron–
sulphur cluster and heme biogenesis, iron binding/stor-
age, and chaperone activity.4–6
Erythropoietin (EPO) is a glycoprotein that acts as a
main regulator for erythropoiesis. Evidence suggests
that both EPO and its receptor are expressed in the
nervous tissue,7,8 and neuroprotective effects have been
shown in animal models of cerebral ischemic
damage.9,10
EPO increases frataxin levels in cultured human lym-
phocytes from FA patients.11 However, frataxin pro-
tein increase is not preceded by mRNA increase,
suggesting that a post-transcriptional mechanism is
involved.12 Two phase II clinical trials have tested EPO
in FA patients. In the first, 12 patients were treated
with 5,000 IU of Epoetin beta thrice a week (TIW) for
8 weeks. This resulted in a 27% frataxin increase in
peripheral blood mononuclear cells (PBMCs), reduc-
tion in oxidative stress markers, and a small clinical
improvement.13 The same group of investigators per-
formed a second trial in which Epoetin beta was given
to 8 patients at a dose of 2,000 IU TIW for 6 months.
The results largely confirmed those of the first trial.
However, 4 patients (50%) required repeated
phlebotomy.14
Patients and Methods
Study Design
We designed an open-label, phase IIa clinical trial to
test the efficacy of two subcutaneous single high dose
of Epoetin alfa (Eprex, Janssen-Cilag, Milano, Italy).
The lower dose was 600 IU/kg body weight (BW)
(max 40,000 IU) and the higher dose was 1200 IU/kg
(max 80,000 IU). Doses were chosen based on the pre-
vious pharmacokinetics studies15 and on the intent to
reproduce a serum EPO concentration similar to previ-
ous in vitro experiments.11 A 3-month washout was
programmed between the doses. Primary endpoint of
the study was the change from baseline in frataxin lev-
els in PBMCs at 24, 48, 96 hours, 7, 15, 30, and 60
days. Secondary endpoints were safetyand tolerability
measured with clinical scale, echocardiography, and
laboratory parameters. The local Ethics Committee
approved the clinical trial, and it was registered at
www.clinicaltrials.gov, NCT00631202.
Patients
Ten patients were enrolled in the study after giving
informed consent (Table 1); 1 patient withdrew his
consent 30 days after the first administration and was
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not considered for endpoint evaluation. Inclusion crite-
ria were clinical and molecular diagnosis of FA (18–50
years of age). Exclusion criteria were idebenone treat-
ment, wheelchair use, renal, hepatic or hematological
disease, positive thrombosis history, hypertension,
acute disease, pregnancy, and breastfeeding.
Quantitative Analysis of Frataxin and EPO
PBMCs were extracted from 15 mL of ethylenedia-
minetetraacetic acid (EDTA)-anticoagulated whole
blood using Leucosep tubes (Greiner Bio-one, Ger-
many). PBMCs were lysed, and total protein was meas-
ured using the bicinchoninic acid (BCA) assay. About
7.125 lg of each protein extract was analyzed in dupli-
cate with lateral-flow immunoassay16 and calibrated
using frataxin protein standard (kit and Hamamatsu
ICA-1000 scanner; Mitosciences, Eugene, OR). Prelimi-
nary test showed an intra-assay and interassay coeffi-
cient of variability both <5%. Data from 31 carriers
and 19 control individuals were analyzed in parallel.
Serum concentrations of EPO were measured using an
enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, MN).
Secondary Outcomes
Laboratory parameters were monitored at screening,
baseline, and 7, 15, 30, and 60 days after each admin-
istration and comprised hematology, urine examina-
tion, coagulation, and a serum routine biochemistry
with iron, ferritin and transferrin determination.
Adverse events and blood pressure were monitored at
each visit. Electrocardiograms were performed at
screening and 30 days after each administration. The
International Cooperative Ataxia Rating Scale
(ICARS)17 was measured at baseline, 7 and 30 days af-
ter each administration, and 6 months after the last
dose.
Conventional M-mode, two-dimensional imaging,
and quantitative regional strain and strain rate were
used to evaluate cardiac morphology and function.
Echocardiography was performed at baseline and 6
months after the second EPO administration.
Statistical Analysis
Statistical analysis for continuous variables was con-
ducted by two-way ANOVA for repeated measures. P
values of less than 0.05 were considered statistically
significant. Posthoc analysis was performed with the
Dunnett’s test to compare basal levels with different
time points (Graphpad Prism 5.0c).
Results
Frataxin
We did not observe significant variations of frataxin
in the 24 hours to 60 days interval, either after the first
or the second EPO administration. Peaks were
observed 96 hours after the first dose (mean increase
8.9%; P ¼ 0.47) and 48 hours after the second
(16.3%; P ¼ 0.34). Surprisingly, when analyzing fra-
taxin levels throughout the study, we found a slow and
sustained increase (Fig. 1). Basal frataxin was 12.7 6 3
pg/lg total protein and rose to 17.1 6 5.8 pg/lg (35%
relative increase from baseline; P < 0.05) 3 months af-
ter the first Epoetin alfa administration. After the sec-
ond injection, frataxin increased to 18.3 6 7 pg/lg
(44% relative increase compared with baseline; P <
0.01) 2 months later. Given this unexpected delayed
effect of Epoetin alfa, we decided to extend the obser-
vation period. At 6 months from the second adminis-
tration, we found frataxin to be 19.5 6 5.4 pg/lg
(54% relative increase from baseline; range 14–144; P
< 0.001). At 12 months, frataxin values were no lon-
ger significantly higher than baseline (16.1 6 9 pg/lg;
P > 0.05).
Table 1. Patient characteristics
Patient Age Sex Age at onset Disease duration GAA1 GAA2 ICARS baseline ICARS frataxin peak*
1 19 M 8 11 709 830 56 61
2 29 F 23 6 800 1000 36 39
3 30 F 18 12 600 1267 58 56
4 25 M 14 11 958 958 51 48
5 43 M 23 20 200 421 25 25
6 22 F 11 11 489 1022 39 36
7 22 M 15 7 734 934 49 52
8 19 M 9 10 752 1041 66 –
9 31 F 15 16 355 561 68 78
10 40 F 28 12 580 780 55 45
Mean 29 6 8.2 17.2 6 6.4 11.8 6 4.2 602.8 6 232 863.7 6 253.9 48.6 6 13.1 48.9 6 15.4
Mean 6 SD for the 9 patients who completed the study.
*ICARS performed 6 months after the second Epoetin alfa administration (month 9 in Fig. 1).
GAA1, triplet repeat number in the minor allele; GAA2, triplet repeat number in the major allele; ICARS, International Cooperative Ataxia Rating Scale.15
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Serum EPO
Twenty-four hours after the first administration, se-
rum EPO increased from 11.2 6 8.6 mIU/mL at base-
line to 1153 6 354 mIU/mL (Supporting Information
Figure). EPO then decreased to basal levels 7 days after
injection. The second injection produced similar results
(19.7 6 19.6 and 3343 6 657 mIU/mL).
Iron
Total iron decreased from 75.0 6 39.1 lg/dl at baseline
to 44.4 6 24.4 lg/dl (P <0.05) at 7 days and returned to
81.1 6 31.5 lg/dl at 30 days. The second injection pro-
duced similar results (83.6 6 46.5, 31.0 6 14.4, 76.8 6
34.3 lg/dl; P < 0.01). Ferritin decreased from 104.9 6
98.7 ng/mL at baseline to 18.56 12.4 ng/mL (P < 0.001)
at 7 days after the first dose and returned to 73.4 6 79.2
ng/mL at 30 days. The higher dose caused similar results
(70.36 90.2, 30.56 41.4, 62.16 77.6 ng/mL, P < 0.01).
Transferrin remained stable for the same time points (first
dose 250.1 6 58.68, 273.4 6 48.5, 244.6 6 58.8 mg/dl;
second dose 285.1 6 53.0, 273.8 6 64.9, 288.1 6 52.3
mg/dl, P ¼ NS). Mean transferrin saturation decreased by
44.6% (P < 0.01) 7 days after the first and 63.2% (P <
0.001) 7 days after the second dose, when compared with
baseline.
Secondary Outcomes
A total of 10 grade 1 adverse events were recorded af-
ter the lower dose and two after the higher dose (myal-
gia, flu-like syndrome, hypotension, nausea, itching and
reaction at injection site, headache, nocturnal sweating,
and extremities warm feeling). Blood pressure and elec-
trocardiograms showed no change during the study. He-
matocrit, erythrocytes, hemoglobin, and all other
laboratory safety parameters were not influenced by
treatment. Echocardiographic measures showed no
change from baseline. As a prototype of myocardial con-
tractility, the left ventricle strain was "19.9 6 5.1% at
basal and "18.5 6 6.7% at 6 months (P ¼ NS). ICARS
was unchanged during the study (Table 1; baseline 48.6
6 13.1 vs. 48.9 6 15.4 at frataxin peak, P ¼ NS).
Discussion
In vivo, our study did not replicate the previous in
vitro findings of an acute increase in frataxin after EPO
stimulation. Although the lack of statistical significance
of the early increase we observed may be because of the
small sample size, any clinical significance of such a
small change is likely to be limited. In contrast, an unex-
pected delayed effect of Epoetin alfa on frataxin levels in
PBMCs was observed 3 months after 600 IU/kg of Epoe-
tin alfa (35% increase). The second injection caused an
additional increase in frataxin up to 54% above base-
line. A carry-over effect cannot be excluded and could
be responsible of the observed effect. Interestingly, the
increase was evident after serum EPO returned to basal
levels, suggesting that a direct stimulation of the EPO re-
ceptor is not involved in the delayed effect. Previous clin-
ical trials13,14 were designed with continuous low dose
administration, and the interval between EPO adminis-
tration and frataxin increase could not be assessed. We
demonstrate that single high dose of EPO can produce a
considerably larger and sustained effect when compared
with low TIW doses. In addition, no hemoglobin
increase was observed, and none of our patients required
phlebotomy, indicating lack of erythropoietic effect of
single high dose of EPO. In contrast, our study failed to
demonstrate a clinical improvement that was reported in
the past trials. This could be explained by a lower sensi-
tivity of ICARS, compared with Friedreich Ataxia Rat-
ing Scale (FARS) or the scale for the assessment and
rating of ataxia (SARA) scale, or by the presence of a
learning effect of repeated measuring in the previous
trials.
Exact effect of EPO on frataxin is unknown. EPO
administration is known to reduce circulating hepci-
din,18 and as a consequence ferroportin inhibition is
released and iron stores are reduced.19 In this study,
EPO reduced transferrin saturation, indicating iron
redistribution from peripheral tissues to the bone mar-
row. The absence of a clear hematopoietic effect
remains unclear. Perhaps, very high single EPO doses
may have a very strong and rapid relocating effect on
iron, but repeated dosing may be necessary to obtain a
hematopoietic effect. This iron relocating effect may be
a clue to explain the delay in frataxin increase. The
sustained effect of EPO remains obscure, and long-last-
ing post-transcriptional effects cannot be excluded.
In conclusion, it is possible to achieve a considerable
increase in frataxin using a very simple administration
scheme of Epoetin alfa with no hematological side
effects. In the absence of a control group, the present
data should still be regarded as preliminary until a
FIG. 1. Frataxin levels after two single doses of Epoetin alfa. Frataxin
levels are shown as pg/lg of total protein extract from the patients
who completed the study (n 5 9, gray bars), carriers (white bar; n 5
31; 25.3 6 4.9 pg/lg total protein), and healthy controls (black bar; n
5 19; 41.3 6 7.5 pg/lg total protein). All values are mean 6 standard
deviation (statistical significance compared with baseline 5 *P < 0.05,
**P < 0.01, ***P < 0.001).
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randomized, placebo-controlled trial, has been per-
formed.
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ABSTRACT
We designed this study to find out more about the rela-
tionship between the sensory effects of Botulinum toxin
type A (BTX) and the clinical benefits of BTX therapy in
patients with cervical dystonia (CD). In 24 patients with
CD, we tested sensory temporal discrimination (STD) in
the affected and two unaffected body regions (neck,
hand, and eye) before and 1 month after BTX injection. In
8 out of the 24 patients with CD, STDT values were tested
bilaterally in the three body regions before, 1 and 2
months after BTX injection. As expected, STD testing dis-
closed altered STD threshold values in all three body
regions tested (affected and unaffected by dystonic
spasms) in patients with CD. STD threshold values
remained unchanged at all time points of the follow-up in
all CD patients. The lack of BTX-induced effects on STD
thresholds suggests that STD recruits neural structures
uninvolved in muscle spindle afferent activation. VC 2010
Movement Disorder Society
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